Biotek-snakken — November 2024
-
Ascelia Pharma Announces Completion of Full Study Report Reinforcing the Successful Outcomes of Orviglance Phase 3 Study SPARKLE
Ascelia Pharma Announces Completion of Full Study Report Reinforcing the Successful Outcomes of Orviglance Phase 3 Study SPARKLE – ASCELIA
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announce ...
(www.ascelia.com)
-
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the completion of the Full Study Report for the pivotal Phase 3 Study for Orviglance
liver imaging drug candidate, which includes the previously announced strong results of primary endpoints. In addition, the results of secondary endpoints further reinforce the successful study outcomes and support the New Drug Application (NDA) process. -
Curasight: Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer https://news.cision.com/curasight/r/clinical-phase-ii-trial-of-upar-pet-in-brain-cancer-patients-published--data-supports-development-of,c4062536
-
Kvartalsrapport Q3: Framgångsrikt utfall av företrädesemission om 105 MSEK förlänger kassalikviditeten till sent 2025
https://www.ascelia.com/sv/ir-media-sv/finansiella-rapporter/
-
FINANSIELL UTVECKLING I SAMMANDRAG FÖR Q3 (jul-sep) 2024
• Rörelseresultatet uppgick till -17,8 MSEK (-21,4 MSEK)
• Vinst per aktie uppgick till -0,42 SEK (-0,63 SEK)
• Kassaflöde från den löpande verksamheten uppgick till -17,0 MSEK (-31,0 MSEK)
• Likvida medel inkl. kortfristiga placeringar uppgick till 95,7 MSEK (39,0 MSEK) -
En presentation för analytiker, investerare och media hålls idag 7 november kl. 10:00. Rapporten presenteras av företagets CEO Magnus Corfitzen, Deputy CEO Julie Waras Brogren och CSO Andreas Norlin. Presentationen kommer att hållas på engelska. Presentationen kan följas live via följande länk:
-
-
Genovis Interim Report January-September 2024
https://mb.cision.com/Main/1712/4062725/3100464.pdf
"Our Best Quarter in the Enzyme Business: Strong Growth and improved profitability"
-
Opsummering: regnskabet viser stærk underliggende vækst i enzym-forretningen, markant forbedret indtjening i Q3, strategisk positiv udvikling med fokus på kernekompetencer, plus der synes at være en klar retning i virksomheden (salg af antistof-forretningen og investering i Sequrna AB).
-
Genovis Q3 2024: Initial take – Stronger than anticipated
https://www.redeye.se/research/1051370/genovis-q3-2024-initial-take-stronger-than-anticipated
(Research Note 2024-11-08 08:49)
Redeye provides its initial take on Genovis' Q3 report, which exceeded expectations across the board. We anticipate a positive relief in the share price, accompanied by upward estimate revisions following today's report.
-
Ascelia Pharma Q3 Update: Cash and progress
(Research Update 2024-11-08 08:21)
After the recent rights issue, Ascelia has SEK 95.7m in cash before support from warrants, and the company has a runway to end 2025. The Full Study Report for Orviglance is completed, and the next stage is to engage in pre-submission meetings with the FDA on the way to a formal submission by mid-2025. Orviglance continues to feature at conferences, which is important as Ascelia is pursuing a partner strategy for the
-
-
Et andet selskab i samme boldgade kunne være Nurix Therapeutics, hvis førende asset er en BTK degrader - en del data kommer på ASH, men som Kymera ligeledes roder med degraders mod IRAK4 og STAT6. De satser lidt mere på partnerskaber (Gilead, Sanofi og Pfizer), mens Kymera har større ambitioner på egen hånd:
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind